教員情報 - 髙田　卓磨

学術雑誌

学会発表

社会における活動

研究課題・受託研究・科研費

受賞学術賞

所属学会

学歴

（最終更新日：2026-01-06 15:34:50）

  タカダ　タクマ   TAKADA Takuma
  髙田　卓磨
   所属   医学研究科医学研究科 (医学部医学科をご参照ください)  先端生命医科学研究所

職種非常勤講師

■ 学術雑誌

1.	原著	Functional analysis of human induced pluripotent stem cell-derived cardiac tissue during endothelial cell network changes 2025/12
2.	原著	Low Body Weight and Long-term Outcomes in Patients with Venous Thromboembolism: Insights from the COMMAND VTE Registry-2. 2025/12
3.	原著	Real-world management and outcomes of venous thromboembolism in patients with cancer and limited life expectancy in the direct oral anticoagulant era: insights from the COMMAND VTE Registry-2. 2025/12
4.	原著	Concomitant Antiplatelet Therapy in Patients With Venous Thromboembolism Treated With Anticoagulants　- Insights From the COMMAND VTE Registry-2. 2025/11
5.	原著	Extended anticoagulation therapy on clinical outcomes in patients with gastrointestinal cancer and isolated distal deep vein thrombosis: Insights from the ONCO DVT Study. 2025/11
6.	原著	Prediction Score for Major Bleeding in Patients With Venous Thromboembolism Receiving Direct Oral Anticoagulants　- Insights From the COMMAND VTE Registry-2. 2025/11
7.	原著	Impact of the Balloon Pulmonary Angioplasty on the Diagnosis of Chronic Thromboembolic Pulmonary Hypertension: From the COMMAND VTE Registry-2. 2025/10
8.	原著	The influence of metastasis on clinical outcomes in patients with cancer-associated isolated distal deep vein thrombosis: A pre-specified subgroup analysis from the ONCO DVT study. 2025/10
9.	原著	Impact of thrombocytopenia in patients with cancer-associated isolated distal deep vein thrombosis treated with edoxaban for 12 months versus 3 months: Insights from the ONCO DVT study. 2025/09
10.	原著	Connexin 43 suppression enhances contractile force in human iPSC-derived cardiac tissues. 2025/08/08
11.	原著	Prolonged Edoxaban in Patients With Low Body Weight and Cancer-Associated Isolated Distal Deep Vein Thrombosis. 2025/08
12.	原著	Differences in risk factors between all-cause and pulmonary embolism-related death in acute pulmonary embolism: insights from the COMMAND VTE registry-2. 2025/07
13.	原著	Edoxaban treatment without initial heparin lead-in for acute venous thromboembolism: insight from the COMMAND VTE registry-2. 2025/06
14.	原著	D-dimer after 3 months of anticoagulation therapy and outcomes in cancer-associated isolated distal deep vein thrombosis. 2025/05
15.	原著	Correction: Predictors of the diuretic response in acute decompensated heart failure patients with severe aortic stenosis: sub-analysis of the LOHAS registry. 2025/03
16.	原著	Management strategies and clinical outcomes of venous thromboembolism in patients with antiphospholipid syndrome in the direct oral anticoagulant era: Insight from the COMMAND VTE Registry-2. 2025/03
17.	その他	Reply to the Comments on “Cardiovascular Prognosis in Limb Ischemia Patients with Heart Failure and Systolic Dysfunction Following Major Amputation” 2025/02/18
18.	原著	Clinical outcomes of cancer-associated isolated distal deep vein thrombosis: a comparison between asymptomatic and symptomatic thrombosis-findings from the ONCO DVT Study. 2025/02
19.	原著	Predictors of the diuretic response in acute decompensated heart failure patients with severe aortic stenosis: sub-analysis of the LOHAS registry. 2025/02
20.	原著	Cardiovascular Prognosis in Limb Ischemia Patients With Heart Failure and Systolic Dysfunction Following Major Amputation. 2024/12/31
21.	原著	Additional mineralocorticoid receptor antagonists in heart failure underdosed with guideline-directed medication 2024/12/19
22.	原著	Net Clinical Benefit of 12-Month Over 3-Month Edoxaban in Cancer-Associated Isolated Distal Deep Vein Thrombosis. 2024/12
23.	原著	Newly Diagnosed Cancer After Diagnosis of Venous Thromboembolism　- Insights From the COMMAND VTE Registry-2. 2024/12
24.	原著	Utility of the modified Ottawa score for identification of more preferable candidates of extended anticoagulation therapy in cancer-associated isolated distal deep vein thrombosis: insight from the ONCO DVT Study. 2024/12
25.	原著	Clinical characteristics and short-term outcomes of patients with critical acute pulmonary embolism requiring extracorporeal membrane oxygenation: from the COMMAND VTE Registry-2. 2024/11
26.	原著	Incidence and risk factors of ischemic stroke in patients with cancer-associated venous thromboembolism: from the Contemporary Management and Outcomes in Patients With Venous Thromboembolism Registry-2. 2024/11
27.	原著	Incidence of Chronic Thromboembolic Pulmonary Hypertension After Pulmonary Embolism in the Era of Direct Oral Anticoagulants: From the COMMAND VTE Registry-2. 2024/11
28.	原著	Rivaroxaban for 18 Months Versus 6 Months in Patients With Cancer and Acute Low-Risk Pulmonary Embolism: An Open-Label, Multicenter, Randomized Clinical Trial (ONCO PE Trial). 2024/11
29.	原著	Association Between White Blood Cell Counts at Diagnosis and Clinical Outcomes in Venous Thromboembolism　- From the COMMAND VTE Registry-2. 2024/10
30.	原著	Initial anticoagulation therapy with single direct oral anticoagulant in patients with intermediate-high risk acute pulmonary embolism: From the COMMAND VTE Registry-2. 2024/10
31.	原著	Selection of Home Treatment and Identification of Low-Risk Patients With Pulmonary Embolism Based on Simplified Pulmonary Embolism Severity Index Score in the Era of Direct Oral Anticoagulants. 2024/10
32.	原著	Impact of Anemia on Clinical Outcomes of Patients With Cancer-Associated Isolated Distal Deep Vein Thrombosis Receiving Edoxaban　- Insights From the ONCO DVT Study. 2024/09
33.	原著	Prognostically Optimal Heart Rate at Discharge in Hospitalized Patients With Heart Failure and Atrial Fibrillation. 2024/08
34.	原著	Statins use and recurrent venous thromboembolism in the direct oral anticoagulant era: insight from the COMMAND VTE Registry-2. 2024/08
35.	原著	Temporal Changes in Long-Term Outcomes of Venous Thromboembolism From the Warfarin Era to the Direct Oral Anticoagulant Era. 2024/08
36.	原著	External validation of the Pulmonary Embolism-Syncope, Anemia, and Renal Dysfunction bleeding score for early major bleeding in patients with acute pulmonary embolism: from the COMMAND VTE Registry-2. 2024/06
37.	原著	Edoxaban, Rivaroxaban, or Apixaban for Cancer-Associated Venous Thromboembolism in the Real World: Insights from the COMMAND VTE Registry-2. 2024/05
38.	原著	Edoxaban for 12 Versus 3 Months in Cancer-associated Isolated Distal Deep Vein Thrombosis According to Different Doses: Insights from the ONCO DVT study. 2024/04
39.	原著	Subclass phenotypes in patients with unprovoked venous thromboembolisms using a latent class analysis. 2024/04
40.	原著	Home Treatment for Active Cancer Patients With Low-Risk Pulmonary Embolism　- A Predetermined Companion Report From the ONCO PE Trial. 2024/03
41.	原著	The impact of renal function on clinical outcomes of patients with cancer-associated isolated distal deep vein thrombosis: Insights from the ONCO DVT study. 2024/03
42.	原著	Cancer-associated venous thromboembolism in the direct oral anticoagulants era: Insight from the COMMAND VTE Registry-2 2024/02
43.	原著	Fragility and long-term clinical outcomes in patients with venous thromboembolism receiving direct oral anticoagulants: From the COMMAND VTE REGISTRY-2. 2024/02
44.	その他	細胞シート開発の最新の話題 2024/01/01
45.	原著	Left Ventricular End-Systolic Diameter May Predict Persistent Heart Failure with Reduced Ejection Fraction. 2023/11
46.	原著	Anticoagulation strategies and long-term recurrence in patients with venous thromboembolism in the era of direct oral anticoagulants. 2023/08
47.	原著	Edoxaban for 12 Months Versus 3 Months in Patients With Cancer Isolated Distal Deep Vein Thrombosis (ONCO DVT study): An Open-label, Multicenter, Randomized Clinical Trial. 2023/08
48.	原著	Renin-angiotensin system inhibitor exerts prognostic effects in HFpEF patients with low baseline chloride level. 2023/02/15
49.	原著	Prognostic impact of guideline-directed medical therapy in patients with heart failure on regular hemodialysis 2023/01/01
50.	総説	細胞シートを用いた再生医療と創薬モデルの開発 2022/07
51.	原著	Prognosis and diastolic dysfunction predictors in patients with heart failure and recovered ejection fraction. 2022/05/24
52.	原著	Functional Evaluation of Human Bioengineered Cardiac Tissue Using iPS Cells Derived from a Patient with Lamin Variant Dilated Cardiomyopathy. 2022/03/30
53.	原著	Impact of anatomical position of the inflow cannula on stroke in patients with left ventricular assist devices 2022/01
54.	原著	Aligned human induced pluripotent stem cell-derived cardiac tissue improves contractile properties through promoting unidirectional and synchronous cardiomyocyte contraction. 2021/12
55.	原著	Nutritional status during hospitalization is associated with the long-term prognosis of patients with heart failure 2021/10/01
56.	症例報告	Heart transplant candidate with medical complexity in the era of prolonged left ventricular assist device support — A case report 2020/10/22
57.	原著	Effect of Transcatheter Aortic Valve Implantation on Renal Function in Patients With Chronic Kidney Disease. 2020/07/01
58.	症例報告	Recurrent takotsubo syndrome with worsening of left ventricular outflow obstruction during haemodialysis: a case report. 2020/02/21
59.	原著	Predictors of neo-aortic valve regurgitation in the long term after arterial switch operation 2020
60.	原著	Impact of Late Ventricular Arrhythmias on Cardiac Mortality in Patients with Acute Myocardial Infarction 2019/07/08
61.	原著	Clinical experience of idarucizumab use in cases of cardiac tamponade under uninterrupted anticoagulation of dabigatran during catheter ablation of atrial fibrillation. 2019/05
62.	原著	Neoatherosclerosis 5 Years After Bioresorbable Vascular Scaffold Implantation. 2018/05
63.	原著	The COFFEE Trial (COmparison of Fractional Flow Reserve Measurements through 4 FrEnch versus 6 FrEnch Diagnostic Catheter). 2018/02
64.	症例報告	失神を契機に成人期にNoonan症候群と診断された1例 2018
65.	原著	Initial and Long-Term Results of a Microcatheter-Based Retrograde Approach for the Endovascular Treatment of Chronic Total Occlusion in Iliac or Femoropopliteal Arteries. 2017/05
66.	その他	Reply: Slender Sheaths Have the Potential to Expand the Use of Transradial Access for Complex CTO-PCI. 2017/05
67.	原著	Transradial Coronary Interventions for Complex Chronic Total Occlusions. 2017/02
68.	原著	Long-Term Outcomes of Successful Endovascular Therapy Via the Retrograde Approach for Below-the-Knee Chronic Total Occlusion in Patients With Critical Limb Ischemia After a Failed Antegrade Approach. 2017/01
69.	症例報告	Persistent Bioresorbable Vascular Scaffold by Optical Coherence Tomography Imaging at 5 Years. 2017/01
70.	原著	Long-term risks for patency loss in patients with hemodialysis after bare self-expandable nitinol stent implantation to femoropopliteal artery occlusive lesions. 2016/11
5件表示
全件表示(70件)

■ 学会発表

1.	Alignment Control of Human iPSC-derived Cardiomyocytes, and the Role of FoxO1 Phosphorylation at Serine 284 by GSK-3β in the Heart. （口頭，特別講演・招待講演など） 2025/10/08
2.	Phosphorylation of FoxO1 at Serine 284 by GSK3β Is Essential for Maintaining Systolic Function in the Heart （口頭，一般） 2025/07/31
3.	Phosphorylation of FoxO1 at Serine 284 by GSK3β Is Essential for Maintaining Systolic Function in the Heart （ポスター掲示，一般） 2025/07/23
4.	血管内皮細胞ネットワーク変動過程におけるヒト人工多能性幹細胞由来心筋組織の機能的変化（ポスター掲示，一般） 2025/03/21
5.	3次元ヒトiPS細胞由来心筋組織の心筋細胞密度の違いによる組織収縮力と同期性への影響（ポスター掲示，一般） 2024/05/11
6.	ヒト心筋組織の収縮機能はコネキシン43の発現量低下により収縮同期性を損なうことなく向上する（口頭，一般） 2024/05/11
7.	Cx43の制御によるヒトiPS細胞由来心臓組織の収縮・同期性への影響（ポスター掲示，一般） 2024/03/22
8.	配向した心筋組織のシート化と三次元配向組織の構築と機能的評価（口頭，一般） 2024/03/21
9.	Anemia Causes Poor Prognosis in Older Patients with Atrial Fibrillation and Heart Failure with Preserved Ejection Fraction （口頭，シンポジウム・ワークショップパネル（指名）） 2024/03/10
10.	Edoxaban for 12 versus 3 Months in Cancer-associated Isolated Distal Deep Vein Thrombosis According to Age: ONCO DVT Study （口頭，一般） 2024/03/10
11.	The Impact of Kidney Function in Cancer-associated Isolated Distal Deep Vein Thrombosis for Anticoagulation Strategy: Sub-analysis of the ONCO-DVT Study （口頭，一般） 2024/03/10
12.	Actual Management of Venous Thromboembolism in Patients with Terminal Cancer. From the COMMAND-VTE Registry-2 （ポスター掲示，一般） 2024/03/09
13.	Clinical Characteristics and Impact of Bleeding Complications in Cancer-Related Isolated Distal Deep Vein Thrombosis: The ONCO DVT Study （ポスター掲示，一般） 2024/03/09
14.	Direct Oral Anticoagulant-Associated Bleeding in Patients with Upper or Lower Gastrointestinal Cancer and Venous Thromboembolism: From the COMMAND VTE Registry-2 （ポスター掲示，一般） 2024/03/09
15.	doxaban for 12 versus 3 Months in Cancer-associated Isolated Distal Deep Vein Thrombosis According to Symptom: ONCO DVT Study （口頭，一般） 2024/03/09
16.	Edoxaban for 12 versus 3 Months in Cancer-associated Isolated Distal Deep Vein Thrombosis According to Distant Metastases: ONCO DVT Study （ポスター掲示，一般） 2024/03/09
17.	Ischemic Stroke in Cancer-associated Venous Thromboembolism in the Era of Direct Oral Anticoagulants: From the COMMAND VTE Registry-2 （口頭，一般） 2024/03/09
18.	Optimal Discharge Heart Rate for Prognosis in Hospitalized HFpEF and HFrEF Patients with Persistent AF （ポスター掲示，一般） 2024/03/09
19.	Real World Long-term Outcomes of Extended Anticoagulation Therapy for Venous Thromboembolism in the Era of Direct Oral Anticoagulant （口頭，一般） 2024/03/09
20.	Edoxaban for 12 versus 3 Months in Cancer-associated Isolated Distal Deep Vein Thrombosis According to Different Doses: ONCO DVT Study （口頭，一般） 2024/03/08
21.	Fibroblasts Regulate Cardiomyocyte Alignment and Enable the Fabrication of 3D Cardiac Tissue with Layered Aligned Cardiomyocytes at Different Angles （口頭，一般） 2024/03/08
22.	Net Clinical Benefit of Edoxaban for 12 versus 3 Months in Cancer-associated Isolated Distal Deep Vein Thrombosis: ONCO DVT Study （口頭，シンポジウム・ワークショップパネル（指名）） 2024/03/08
23.	Preventive Effects of Gastric Antisecretory against Gastrointestinal Bleeding in Cancer Patients Treated with Edoxaban: Insight from the ONCO DVT Study （口頭，一般） 2024/03/08
24.	Regulation of Connexin 43 in Human iPS Cell-derived Cardiomyocytes Affects the Contractility, but not Synchrony in the Cardiac Tissues （口頭，一般） 2024/03/08
25.	Temporal Change of Clinical Features and Outcomes in Venous Thromboembolism from the Warfarin Era to the Direct Oral Anticoagulant Era （口頭，シンポジウム・ワークショップパネル（指名）） 2024/03/08
26.	Fabrication of Quasi-isotropic layered 3D tissue by aligned human iPS cell-derived cardiomyocyte （口頭，一般） 2024/02/10
27.	Construction of three-dimensional iPS myocardial tissue by stacking oriented sheets （口頭，一般） 2023/12/09
28.	Suppression of Connexin 43 in Human iPS cell-derived Cardiac Tissues Improves the Contractile Force through Promoting Cardiomyocytes Proliferation （口頭，一般） 2023/12/09
29.	Fabrication of Quasi-isotropic Layered 3D Tissue by Aligned Human IPS Cell-derived Cardiomyocytes （口頭，一般） 2023/12/02
30.	配向した心筋組織のシート化と三次元異方性配向組織の構築（ポスター掲示，一般） 2023/11/24
31.	Alignment Control of Human iPS cell-derived Cardiomyocytes Improves the Cardiac Tissue Function through Synchronous Contraction （口頭，一般） 2023/11/07
32.	ヒトiPS細胞由来心臓組織におけるコネキシン43の抑制は、心筋細胞増殖を介して収縮力を向上させる（口頭，一般） 2023/10/19
33.	High rate of right ventricular pacing causes poor prognosis in patients with heart failure with preserved ejection fraction （口頭，一般） 2023/10/06
34.	High-dose Loop Diuretic Cancels Prognostic Impact of Serum Chloride Level in Patients with Heart Failure （口頭，一般） 2023/10/06
35.	Optimizing Heart Rate Control at Discharge for Improved Prognosis in Hospitalized Patients with Heart Failure and Atrial Fibrillation （口頭，一般） 2023/10/06
36.	Prognostic impact of anemia in elderly patients with hospitalized heart failure （口頭，シンポジウム・ワークショップパネル（指名）） 2023/10/06
37.	Prognostically Optimal Heart Rate at Discharge in Hospitalized Patients with Heart Failure and Atrial Fibrillation （口頭，一般） 2023/08/26
38.	Safety and effectiveness of initial high-dose anticoagulation therapy for cancer-associated venous thromboembolism in the real world: insight from the COMMAND VTE Registry-2 （口頭，一般） 2023/08/25
39.	Clinical characteristics and outcomes of super-low-dose edoxaban of 15 mg in patients with acute venous thromboembolism: insight from the COMMAND VTE Registry-2 （口頭，一般） 2023/08
40.	Clinical features and long-term outcomes of cancer-associated venous thromboembolism: transition from the warfarin era to the direct oral anticoagulant era （口頭，一般） 2023/08
41.	Clinical features and long-term outcomes of venous thromboembolism in the warfarin era versus in the direct oral anticoagulant era （口頭，一般） 2023/08
42.	Clinical long-term outcomes in fragile patients with venous thromboembolism receiving direct oral anticoagulant: From the COMMAND VTE Registry-2 （口頭，一般） 2023/08
43.	Different impact of each score component in the simplified PESI score on acute mortality of patients with pulmonary embolism in the era of direct oral anticoagulant （口頭，一般） 2023/08
44.	External validation of PE-SARD bleeding score for early major bleeding in patients with acute pulmonary embolism: Insight from the COMMAND VTE Registry-2 （口頭，一般） 2023/08
45.	Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism in the era of direct oral anticoagulants: from the COMMAND VTE Registry-2 （口頭，一般） 2023/08
46.	Initial anticoagulation therapy with direct oral anticoagulants in patients with intermediate-high-risk pulmonary embolism: from the COMMAND VTE Registry-2 （口頭，一般） 2023/08
47.	The incidence and risk factors of newly-diagnosed cancer after diagnosis of venous thromboembolism: from the COMMAND VTE Registry-2 （口頭，一般） 2023/08
48.	Alignment control of iPS cells-derived cardiomyocytes improve contractile properties of the entire cardiac tissue through each cardiomyocyte synchronous contraction （ポスター掲示，一般） 2023/05/30
49.	パターン化配向基材と線維芽細胞を用いた配向心筋シートの開発（口頭，一般） 2023/03/25
50.	ヒトiPS細胞由来心筋組織の機能的成熟化への挑戦-GJA1遺伝子の過剰発現による収縮能に対する影響- （口頭，一般） 2023/03/25
51.	薄膜エレクトロニクスを用いた細胞外電位と張力同時計測システムにおける持続的電気刺激法の開発（口頭，一般） 2023/03/25
52.	Bioengineered tissue approach for understanding the interaction between structure maintenance and the cardiomyocyte synchronous contraction （口頭，シンポジウム・ワークショップパネル（指名）） 2023/03/12
53.	Current Use of Inferior Vena Cava Filters in Japan in the Era of DOACs from the COMMAND VTE Registry-2 （口頭，一般） 2023/03/12
54.	Development of pulsatile human cardiac tissue with vascularization and helical structure for direct circulation support through perivascular transplantation （口頭，シンポジウム・ワークショップパネル（公募）） 2023/03/12
55.	Fibroblast alignment control regulates cardiomyocyte alignment in the bioengineered cardiac tissue （口頭，一般） 2023/03/12
56.	Initial Anticoagulation Strategy in Pulmonary Embolism Patients with Right Ventricular Dysfunction and Elevated Troponin Levels: From the COMMAND VTE Registry-2 （口頭，一般） 2023/03/12
57.	Patient Characteristics and Clinical Outcomes among Direct Oral Anticoagulants for Cancer-Associated Venous Thromboembolism: From the COMMAND VTE Registry-2 （口頭，一般） 2023/03/12
58.	Anticoagulation Strategies and Clinical Outcomes of Venous Thromboembolism in the Era of Direct Oral Anticoagulant: From the COMMAND VTE Registry-2 （口頭，シンポジウム・ワークショップパネル（指名）） 2023/03/11
59.	Clinical Characteristics and Outcomes of Venous Thromboembolism Comparing Patients with and without Initial Intensive High-dose Anticoagulation by Rivaroxaban and Apixaban （口頭，一般） 2023/03/11
60.	Comparison of Clinical Characteristics and Outcomes of Venous Thromboembolism (VTE) between Young and Elder Patients: From the COMMAND VTE Registry-2 （口頭，一般） 2023/03/11
61.	Direct Oral Anticoagulants-Associated Bleeding Complications in Patients with Gastrointestinal Cancer and Venous Thromboembolism: From the COMMAND VTE Registry-2 （口頭，一般） 2023/03/11
62.	Influence of Fragility on Clinical Outcomes in Patients with Venous Thromboembolism and Direct Oral Anticoagulant: From the COMMAND VTE Registry-2 （口頭，一般） 2023/03/11
63.	Off-Label Under- and Overdosing of Direct Oral Anticoagulants in Patients with Venous Thromboembolism: From the COMMAND VTE Registry-2 （口頭，一般） 2023/03/11
64.	The Association between Statin Use and Recurrent Venous Thromboembolism: From the COMMAND VTE Registry-2 （口頭，一般） 2023/03/11
65.	Actual Management of Venous Thromboembolism Complicated by Antiphospholipid Antibody Syndrome in Japan. From the COMMAND VTE Registry-2 （口頭，一般） 2023/03/10
66.	Chronic Thromboembolic Pulmonary Hypertension after Acute Pulmonary Embolism in the Era of Direct Oral Anticoagulants: From the COMMAND VTE Registry-2 （口頭，一般） 2023/03/10
67.	Clinical Characteristics and Outcomes in Patients with Cancer-Associated Venous Thromboembolism According to Cancer Sites: From the COMMAND VTE Registry-2 （口頭，一般） 2023/03/10
68.	Clinical Characteristics, Anticoagulation Strategies and Outcomes Comparing Patients with and without History of Venous Thromboembolism: From the COMMAND VTE Registry-2 （口頭，一般） 2023/03/10
69.	Even Moderate Tricuspid Regurgitation Leads to a Poor Prognosis in Patients with Heart Failure and Preserved Ejection Fraction （口頭，シンポジウム・ワークショップパネル（指名）） 2023/03/10
70.	How Does the Major Amputation Affect the Prognosis in CLTI Patients with Heart Failure? （口頭，シンポジウム・ワークショップパネル（指名）） 2023/03/10
71.	Impact of Overexpression of GJA1 on Human iPS Cell-derived Cardiac Tissue with Disarray of Cardiomyocytes （口頭，一般） 2023/03/10
72.	Management Strategies and Outcomes of Cancer-Associated Venous Thromboembolism in the Era of Direct Oral Anticoagulants: From the COMMAND VTE Registry-2 （口頭，一般） 2023/03/10
73.	Risk Factor for Major Bleeding during Direct Oral Anticoagulant Therapy in Patients with Venous Thromboembolism: From the COMMAND VTE Registry-2 （口頭，一般） 2023/03/10
74.	Risk Factors of Bleeding during Anticoagulation Therapy for Cancer-associated Venous Thromboembolism in the DOAC Era: From the COMMAND VTE Registry-2 （口頭，一般） 2023/03/10
75.	The Incidence of Occult Cancer after Diagnosis of Venous Thromboembolism in the Current Era: From the COMMAND VTE Registry-2 （口頭，一般） 2023/03/10
76.	Triple Guideline Directed Medical Therapy for Octogenarian Patients with Heart Failure and Preserved Ejection Fraction （口頭，シンポジウム・ワークショップパネル（指名）） 2023/03/10
77.	Utility and Application of Simplified PESI Score for Identification of Low-risk Patients with Pulmonary Embolism in the Era of DOAC （口頭，一般） 2023/03/10
78.	担癌患者における抗凝固療法導入の実態（口頭，一般） 2022/11/30
79.	HFpEF症例の三尖弁閉鎖不全合併は中等度でも予後不良である（口頭，一般） 2022/10/23
80.	RAS阻害薬が有効な患者を見出す血清クロール値を用いた新しいHFpEFの分類法（口頭，シンポジウム・ワークショップパネル（指名）） 2022/10/21
81.	維持透析を伴うHFrEF患者にガイドライン治療薬は予後に影響するか？（口頭，シンポジウム・ワークショップパネル（指名）） 2022/10/21
82.	初回記録された心房細動を伴う心不全入院患者の発作性心房細動と持続性心房細動の退院後の予後比較（口頭，シンポジウム・ワークショップパネル（公募）） 2022/10/21
83.	Even moderate tricuspid regurgitation leads to a poor prognosis in hospitalized patients with heart failure and preserved ejection fraction （ポスター掲示，一般） 2022/08/26
84.	頭位捻転によるAHIへの影響について（口頭，一般） 2022/06/30
85.	New insights on the pathophysiology of non-genetic heart disease （口頭，シンポジウム・ワークショップパネル（指名）） 2022/03/13
86.	心不全患者における栄養障害の再評価によるフレイル・サルコペニアの予防と予後の層別化（口頭，シンポジウム・ワークショップパネル（その他）） 2022/03/13
87.	配向制御したヒトiPS細胞由来心筋組織は一方向性かつ同期的収縮を促進し収縮特性が向上する（口頭，一般） 2022/03/01
88.	Breakthroughs in the Pathophysiology and Treatment of HFpEF(Renin-angiotensin System Inhibitor Gives Lights on the Prognosis of HFpEF Patients if They Have Low Chloride Level) （口頭，シンポジウム・ワークショップパネル（指名）） 2022/03
89.	Heart Rate Reduction Brings Prognostic Benefit in Hospitalized Heart Failure Patients with Atrial Fibrillation （口頭，一般） 2022/03
90.	Left Ventricular End-systolic Dimension can Predict Recovery of Left Ventricular Dysfunction among Patients with Heart Failure and Reduced Ejection Fraction （口頭，一般） 2022/03
91.	Functional differences between the aligned and non-aligned human cardiac tissue （口頭，一般） 2021/12/11
92.	左室駆出率が改善した心不全患者において拡張機能障害の残存は予後不良因子となる（口頭，一般） 2021/12/04
93.	配向制御による同期的収縮を介したヒトiPS細胞由来心筋組織の収縮特性の向上（口頭，一般） 2021/11/20
94.	Baseline QRS Duration >140 msec is Associated With Poor In-Hospital Prognosis of Patients With Acute Myocarditis （ポスター掲示，一般） 2021/11/13
95.	Cardiomyocyte alignment control promotes the electrical integration and improve the contractile function of human cardiac tissue （ポスター掲示，一般） 2021/11/13
96.	Alignment control of human induced pluripotent stem cell-derived cardiomyocytes promotes the synchronous cardiomyocyte contraction in the cardiac tissue （ポスター掲示，一般） 2021/10/27
97.	左室駆出率が改善した心不全患者においても拡張機能障害の残存が予後不良因子となる（口頭，一般） 2021/10/02
98.	Prognostic Predictors of Patients with Acute Myocarditis -Multicenter Observational Study- （口頭，一般） 2021/10/01
99.	Prognostic advantage of optimal medical therapy is NOT cancelled in hospitalized heart failure patients receiving regular hemodialysis （ポスター掲示，一般） 2021/08/27
100.	Heart failure re-hospitalization differently affects the following mortality in patients with reduced, mid-range and preserved LVEF （口頭，一般） 2021/08
101.	Low serum chloride level gives renin-angiotensin system inhibitor a prognostic impact in heart failure patients with preserved ejection fraction （口頭，一般） 2021/08
102.	Aligned Human iPS cell-derived Cardiac Tissue Improves the Systolic and Relaxation Function through Promoting Synchronous Cardiomyocyte Contraction （口頭，一般） 2021/03/26
103.	Improvable nutritional status during hospitalization is associated with long-term prognosis in hospitalized patients with heart failure （口頭，一般） 2021/03/26
104.	Makoto Kishihara, Kentaro Jujo, Takuma Takada, Takuro Abe, Shota Shirotani, Nana Endo, Shonosuke Watanabe, Yuichiro Minami, Nobuhisa Hagiwara （口頭，一般） 2021/03/26
105.	MitraClip For Severe Mitral Valve Regurgitation Increased Stroke Volume Compared To Surgical Repair Independent Of Left Ventricular Ejection Fraction （口頭，一般） 2021/03/26
106.	Predictors of Normalization of Left Ventricular Systolic Function After Acute Myocarditis -Multicenter Observational Study- （口頭，一般） 2021/03/26
107.	ヒトiPS細胞由来心筋細胞の配向制御による心筋組織の収縮特性と成熟化への影響（ポスター掲示，一般） 2021/03/11
108.	機能性僧帽弁閉鎖不全症に対するMitraClipは左室駆出率にかかわらず、外科的修復に比べて一回拍出量を増加させる(MitraClip for Functional Mitral Valve Regurgitation Increased Stroke Volume Compared to Surgical Repair Independent of Left Ventricular Ejection Fraction) （口頭，一般） 2021/03
109.	急性心筋炎後の左室収縮機能の回復を予測する因子　多施設共同観察研究(Predictors of Left Ventricular Systolic Functional Recovery after Acute Myocarditis: Multicenter Observational Study) （口頭，一般） 2021/03
110.	Increase in Serum Chloride Level During Hospitalization Leads to Improved Clinical Outcomes in Patients With Heart Failure （口頭，一般） 2020/11/13
111.	Predictors of Normalization of Left Ventricular Systolic Function After Acute Myocarditis -multicenter Observational Study （口頭，一般） 2020/11/13
112.	Functional evaluation of aligned human iPS cell-derived cardiac tissue on micro-processed gel （口頭） 2020/09/27
113.	Preoperative Transaortic Pressure Gradient Predicts Renal Functional Improvement after Transcatheter Aortic Valve Implantation in Patients with Chronic Kidney Disease （口頭，一般） 2020/07/27
114.	The Novel Strategy for Fabricating Aligned Human iPS Cell-derived Cardiac Tissue Model for Disease Research and Drug Development （ポスター掲示，一般） 2020/07/27
115.	左室流出路狭窄を伴うたこつぼ症候群が再発した透析患者の一例（口頭，一般） 2019/09/15
116.	真菌感染症ならびに腎機能障害を伴った移植待機患者に対し心臓移植後慎重に免疫抑制剤の調節を行い、重大な合併症なく退院しえた一例（口頭，一般） 2019/05/26
117.	Predictors of Neo Aortic Valve Regurgitation After Arterial Switch Operation in Long- Term （口頭，一般） 2019/03/31
118.	LVAD植込み後の脳血管障害発症に関する心臓超音波検査を用いた予測因子（口頭，一般） 2019/02/02
119.	補助人工心臓植え込み後の心室頻拍に対してアブレーション治療を行った一例（口頭，一般） 2018/12/15
120.	抗HLA抗体陽性および真菌感染状態の移植待機患者における移植管理への考案（口頭，一般） 2018/10/13
121.	心臓移植後急世紀CVHF療法を要した症例の検討（口頭，一般） 2018/10/03
122.	Bifurcation lesionに対する多面的アプローチ　分岐部病変に対するModified Jailed Balloon Techniqueの有効性と安全性（口頭，一般） 2018/08
123.	Endoluminal bypassの治療適応と今後の展望　大腿膝窩動脈病変に対するステントグラフト留置の中期成績（口頭，一般） 2018/08
124.	下肢虚血を合併した大動脈解離に大動脈開窓術を施行した4症例の長期予後（口頭，一般） 2018/08
125.	透析患者と非透析患者における遠位橈骨動脈穿刺後の橈骨動脈閉塞率の比較（口頭，一般） 2018/08
126.	日本人患者における石灰化病変に対するOrbital Atherectomy （口頭，一般） 2018/08
127.	急性心筋梗塞患者における心室性不整脈の発現時期と予後の関係性(Relationship between the Timing of Ventricular Arrhythmia and Prognosis in Patients with Acute Myocardial Infarction) （口頭，一般） 2018/03
128.	高度Killip分類の急性心筋梗塞患者における死亡の予測因子(Predictors of Death in Acute Myocardial Infarction Patients with High Killip Classes) （口頭，一般） 2018/03
129.	左common trunkが長い患者に対する第2世代クライオバルーンを用いた非セグメント冷却アプローチ　施術所見と臨床転帰(Non-segmental Branch Freezes Approach for Patients with a Long Left Common Trunk Using Second-generation Cryoballoon: Procedural Findings and Clinical Outcome) （口頭，一般） 2018/03
130.	早期、晩期および超晩期ステント血栓症患者における長期転帰の比較(Comparison of Long-term Outcomes among the Patients with Early, Late, and Very Late Stent Thrombosis) （口頭，一般） 2018/03
131.	A New Technique for Box Isolation Using 2nd‒Generation Cryoballoon for Persistent Atrial Fibrillation （口頭，一般） 2017/09/14
132.	Safety of Cryoballoon Ablation Compared with Radiofrequency Catheter Ablation for the Elderly Patients with Paroxysmal Atrial Fibrillation （口頭，一般） 2017/09/14
133.	右上大静脈欠損を伴う左上大静脈遺残に発作性上室性頻拍を合併した稀な1例（口頭，一般） 2017/09/09
134.	失神を契機に発見されたNoonan症候群の一例（口頭，一般） 2017/09/09
135.	心室細動で発症した成人Anomalous origin of the left coronary artery from the pulmonary arteryの1例（口頭，一般） 2017/09/09
136.	迅速な病理診断が早期診断、治療方針に大きく影響した好酸球性心筋炎の一例（口頭，一般） 2017/09/09
137.	日本人における自己拡張型デバイスとバルーン拡張型デバイス留置後の長期の弁機能評価と耐久性について（口頭，一般） 2017/09
138.	High Killip classにおける予後改善を目指したPCI　TRI、One-time PCIを含めて（口頭，一般） 2017/07
139.	エベロリムス溶出性生体吸収性ステントの日本人における5年臨床成績の検討（口頭，一般） 2017/07
140.	重症大動脈弁狭窄症例における中等度冠動脈狭窄病変に対するiFRの有効性についての検討（口頭，一般） 2017/07
141.	新しいSwitch back法　安全かつ確実な鼠径穿刺（口頭，一般） 2017/07
142.	早期経皮的冠動脈形成術を施行した急性心筋梗塞患者における心室性不整脈と心臓死との関係（口頭，一般） 2017/07
143.	分岐部病変に対するModified Jailed Balloon Techniqueの有用性（口頭，一般） 2017/07
144.	本邦における狭心症患者へのBioresorbable vascular scaffold植え込み後の長期成績（口頭，一般） 2017/07
145.	Everolimus溶出性生体吸収性血管スキャフォールドで治療された日本人患者の5年臨床転帰(Five-year Clinical Outcomes of Japanese Patients Treated with the Everolimus-Eluting Bioresorbable Vascular Scaffold) （口頭，一般） 2017/03
146.	Primary PCI後の患者の心臓死亡率に対する遅発型心室性不整脈の影響(The Impact of Late Ventricular Arrhythmia on Cardiac Mortality in Patients After Primary Percutaneous Coronary Intervention) （口頭，一般） 2017/03
147.	高齢心房細動患者に対する第2世代クライオバルーンアブレーションの安全性(Safety of Second-Generation Cryoballoon Ablation for the Elderly Patients with Atrial Fibrillation) （口頭，一般） 2017/03
148.	持続性心房細動において肺静脈隔離術単独施行と比較した肺静脈隔離術後の連続的デフラグメンテーションアプローチにおける1年間フォローアップ転帰(1-year Follow-up Outcome of Sequential Defragmentation Approaches after Pulmonary-vein Isolation Compared to Only Pulmonary-vein Isolation in Persistent Atrial Fibrillation) （口頭，一般） 2017/03
149.	重度大動脈弁狭窄患者の中等度冠動脈狭窄に対する瞬時血流予備量比の診断能(Diagnostic Performance of Instantaneous Wave Free Ratio for Intermediate Coronary Artery Stenosis in Patients with Severe Aortic Valve Stenosis) （口頭，一般） 2017/03
150.	入院後7日未満で退院した急性心筋梗塞患者の予後(Prognosis of Acute Myocardial Infarction Patients Who Discharged from Hospital Earlier than Seven Days) （口頭，一般） 2017/03
151.	Modified Jailed Balloon Technique　分岐部PCIにおける側枝閉塞を避けるための新テクニック（口頭，一般） 2016/07
152.	ロータブレーター使用におけるマイクロカテーテル通過を目的としたBuggy Wire Techniqueの有用性（口頭，一般） 2016/07
153.	非保護左冠動脈主幹部に対してBare Metal Stentを用いた経皮的冠動脈形成術施行患者の10年後の臨床成績の検討（口頭，一般） 2016/07
154.	My Most Memorable Bifurcation Case （口頭，一般） 2016/06
155.	CHADS2スコアが高い患者において心房細動に対するアブレーション後に経口抗凝固療法を中断するリスクおよび安全性(The Risk and Safety of Discontinuing Oral Anticoagulation Therapy after Ablation for Atrial Fibrillation in Patients with High CHADS2 Score) （口頭，一般） 2016/03
156.	Primary PCIによる治療を受けた急性心筋梗塞患者における慢性完全閉塞血行再建の予後への影響(The Prognostic Impact of Chronic Total Occlusion Revascularization in Patients with Acute Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention) （口頭，一般） 2016/03
157.	RAAS阻害薬は急性心筋梗塞後にβ遮断薬を服用中の患者の脳卒中を減らす(RAAS Inhibitor Reduces Stroke Following Acute Myocardial Infarction Patients Taking Β-blocker) （口頭，一般） 2016/03
158.	ベアメタルステントを用いた経皮的冠動脈インターベンション後の非保護左冠動脈主幹部病変を有する患者の10年後の転帰(10-year Outcomes in Patients with Unprotected Left Main Coronary Artery Disease after Percutaneous Coronary Intervention with Bare Metal Stent) （口頭，一般） 2016/03
159.	改変Jailedバルーン法　分岐部病変に対する経皮的冠動脈インターベンションに関連する側枝閉塞回避のための新規手技(Modified Jailed Balloon Technique: A Novel Technique to Avoid Side Branch Occlusion Regarding with Percutaneous Coronary Intervention for Bifurcation Lesions) （ポスター掲示，一般） 2016/03
160.	急性心筋梗塞に対するprimary PCIを施行される患者における血清potassium濃度が心室性不整脈に与える影響(The Impact of Serum Potassium Level on Ventricular Arrhythmia in Patients Undergoing Primary Percutaneous Coronary Intervention with Acute Myocardial Infarction) （口頭，一般） 2016/03
161.	浅大腿動脈病変に対する薬剤溶出ステント留置後の亜急性閉塞の臨床的影響(Clinical Impact of Subacute Occlusion Following Drug Eluting Stent Implantation for Superficial Femoral Artery Lesions) （口頭，一般） 2016/03
162.	発作性心房細動に対するカテーテルアブレーション後の心拍変動は再発を予測する(Heart Rate Variability can Predict the Recurrence after Catheter Ablation for Paroxysmal Atrial Fibrillation) （口頭，一般） 2016/03
163.	Buddy wire techniqueを用いてmicro catheterを進めることでRotablatorに成功した高度石灰化病変の一例（口頭，一般） 2015/11/20
164.	軽症ラクナ梗塞患者における経口普通入院食摂取時の栄養状態悪化（口頭，一般） 2015/03/26
165.	大動脈炎症候群に皮膚型結節性多発動脈炎を合併した1例（口頭，一般） 2014/12
166.	PCI後に急性食道炎を発症した1例（口頭，一般） 2013/06/15
167.	チアマゾール（MMI）内服中に発症したANCA関連顕微鏡的多発血管炎の1例（口頭，一般） 2012/09/08
5件表示
全件表示(167件)

■ 社会における活動

1.	2024/06	(座長) 第272回日本循環器学会関東甲信越地方会　一般演題「心不全/他」
2.	2024/02	(講師) 茨城高等学校・茨城中学校　医学コース　模擬授業
3.	2023/12	(座長) 第270回日本循環器学会関東甲信越地方会　一般演題「心筋炎・心筋症2」
4.	2023/12	(座長) Cardiovascular and Metabolic Week 2023 Keynote lecture 2
5.	2023/07	(座長) 第45回未来医学研究会大会「既成概念を打ち破る先端医療　~think outside the box~」

■ 研究課題・受託研究・科研費

1.	2023/04～	心筋細胞の配向制御による心筋組織機能向上の機序解明若手研究
2.	2022/01～2023/12	拡張障害の改善を目指した配向制御に伴う心筋細胞同期的収縮制御機構の解明競争的資金等の外部資金による研究
3.	2021/12～2022/11	心不全の病態解明を目指した配向制御に伴う心筋細胞同期的収縮制御機構の解明競争的資金等の外部資金による研究

■ 受賞学術賞

1.	2024/05	第10回日本心筋症研究会 YIAセッション最優秀賞
2.	2023/05	女子医大医師会賞
3.	2021/12	第262回日本循環器学会関東甲信越地方会 Clinical Research Award　最優秀賞
4.	2020/10	第4回日本循環器学会基礎研究フォーラム（BCVR)　Encouragement Award

■ 所属学会

1.	2021～	国際心臓研究会（ISHR）日本部会
2.	2020～	日本心不全学会
3.	2019～	再生医療学会
4.	2018～	心筋生検研究会
5.	2018～	日本心臓病学会
6.	2016～	日本不整脈心電学会
7.	2015～	日本心血管インターベンション治療学会
8.	2012～	日本循環器学会
9.	2012～	日本内科学会
5件表示
全件表示(9件)

■ 学歴

1.	2019/04～2022/03	東京女子医科大学医学研究科博士課程修了博士(医学)
2.	2006/04～2012/03	大阪医科大学医学部医学科卒業学士(医学)